J9144 Insurance Policy Changes

HCPCS J9144 is officially defined as "Injection, daratumumab, 10 mg and hyaluronidase-fihj." HCPCS J9144 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9144 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.